Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study

Epilepsy Research
P Tanganelli, G Regesta

Abstract

The clinical efficacy and safety of vigabatrin (VGB) as add-on therapy for pharmaco-resistant focal epilepsies is well established. However, for an objective evaluation, the effects of the drug in the monotherapy of newly diagnosed subjects should be determined. With this aim, VGB was compared, in a randomized, response conditional cross-over study, with carbamazepine (CBZ), the most widely prescribed drug in focal epilepsies. Fifty-one patients with complex partial (CP) seizures were randomly assigned to either the VGB or the CBZ group and evaluated after an initial 4 month period. The cross-over to the alternative drug was carried out, for an analogous period, only in cases with persisting seizures or in the presence of intolerable side effects. Patients who did not respond to either drug were subsequently treated with a combination of VGB and CBZ. No significant difference was revealed in the efficacies of VGB and CBZ; a complete control of seizures was obtained in 17/37 patients (45.9%) treated with VGB and in 20/39 patients (51.3%) treated with CBZ. The side effects were somewhat more frequent (41%) and severe with CBZ than with VGB (21.6%). The power to detect a 20% difference between the two drugs was 75%. The combinatio...Continue Reading

References

Apr 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·A TartaraE Perucca
Mar 1, 1989·Epilepsy Research·L CocitoC Loeb

❮ Previous
Next ❯

Citations

Dec 7, 2000·Mental Retardation and Developmental Disabilities Research Reviews·J M Pellock, L D Morton
Jun 26, 2004·Current Neurology and Neuroscience Reports·Samuel Wiebe
Aug 15, 2000·Epilepsy Research·E PeruccaT Tomson
Nov 26, 2002·Epilepsy Research·Charles L P Deckers
Feb 11, 2003·Epilepsy Research·C L P DeckersD Schmidt
Apr 21, 1999·Epilepsy Research·G Regesta, P Tanganelli
Jan 15, 1999·Seizure : the Journal of the British Epilepsy Association·M Baldy-MoulinierE Perucca
Nov 25, 2000·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·M Zgorzalewicz, B Galas-Zgorzalewicz
Jan 11, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·H StefanO Steinlein
Mar 13, 2002·European Journal of Pain : EJP·Emilio Perucca
Oct 26, 1999·Epilepsia·J A French
Aug 26, 2009·Epilepsia·Jacqueline A French, Edward Faught
Oct 24, 2009·Neuropsychiatric Disease and Treatment·Elizabeth J WaterhouseSoundarya N Gowda
Jan 11, 2007·Drugs·Ricardo M Santaella, Frederick W Fraunfelder
Mar 13, 2002·CNS Drugs·Charles L P Deckers
Aug 14, 2008·CNS Drugs·Gina M Kennedy, Samden D Lhatoo
Feb 20, 2002·British Journal of Clinical Pharmacology·John S Duncan
Mar 13, 2003·Mayo Clinic Proceedings·Randa G Jarrar, Jeffrey R Buchhalter
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P H McCabe
Oct 5, 2007·Seizure : the Journal of the British Epilepsy Association·Jukka PeltolaAnssi Auvinen
May 30, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Pieter D KnoesterHans L Severens
Oct 26, 2016·Pharmacotherapy·Marília Silveira de Almeida CamposLeonardo Régis Leira Pereira
Jan 1, 1997·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·C D Ferrie, J H Livingston
Jan 1, 2012·Journal of Central Nervous System Disease·James W MitchellAndrea E Cavanna
Nov 19, 2015·The Cochrane Database of Systematic Reviews·Yousheng XiaoHongye Luo
Dec 20, 2019·Expert Review of Neurotherapeutics·Alberto VerrottiVincenzo Belcastro
Apr 29, 1998·Current Opinion in Neurology·J W Sander
Jan 12, 2000·The Annals of Pharmacotherapy·B E GidalJ T Gilman
Nov 25, 1998·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A Guberman
Nov 5, 2005·CNS Drugs·Emilio Perucca, Patrick Kwan
Nov 25, 1998·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·J H Schneiderman
Jul 24, 2021·Neuropsychopharmacology Reports·Tahir Hakami
Aug 17, 2021·Journal of Epilepsy Research·Jun-Sang SunwooDae-Won Seo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.